ArticleThe Journal of clinical investigation2012
Cooperation between Rb and Arf in suppressing mouse retinoblastoma.
Article in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Retinoblastoma tumor cell proliferation is negatively associated with an immune gene expression signature and increased immune cells.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Clinical, Genomic, and Pharmacological Study ofCancers · 2020Article
- Identification of microRNA-mRNA regulatory networks and pathways related to retinoblastoma across human and mouse.International journal of ophthalmology · 2020Article
- Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235.Oncotarget · 2017Article
- A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence.The Journal of clinical investigation · 2017Article
- Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes.Scientific reports · 2016Article
- Overview of recurrent chromosomal losses in retinoblastoma detected by low coverage next generation sequencing.Cancer genetics · 2016Review
- Apoptotic and autophagic pathways with relevant small-molecule compounds, in cancer stem cells.Cell proliferation · 2015Review
- Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.Molecular cancer · 2015Article
- Article
- Cancer: The origin of human retinoblastoma.Nature · 2014Article
- Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation.Oncogene · 2014Article
- E2f2 induces cone photoreceptor apoptosis independent of E2f1 and E2f3.Cell death and differentiation · 2013Article
- Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation.Nature cell biology · 2012Article
- The retinoblastoma tumor suppressor and stem cell biology.Genes & development · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Retinoblastoma is a pediatric cancer that has served as a paradigm for tumor suppressor gene function. Retinoblastoma is initiated by RB gene mutations, but the subsequent cooperating mutational events leading to tumorigenesis are poorly characterized. We investigated what these additional genomic alterations might be using human retinoblastoma samples and mouse models. Array-based comparative genomic hybridization studies revealed deletions in the CDKN2A locus that include ARF and P16INK4A, both of which encode tumor suppressor proteins, in both human and mouse retinoblastoma. Through mouse genetic analyses, we found that Arf was the critical tumor suppressor gene in the deleted region. In mice, inactivation of one allele of Arf cooperated with Rb and p107 loss to rapidly accelerate retinoblastoma, with frequent loss of heterozygosity (LOH) at the Arf locus. Arf has been reported to exhibit p53-independent tumor suppressor roles in other systems; however, our results showed no additive effect of p53 and Arf coinactivation in promoting retinoblastoma. Moreover, p53 inactivation completely eliminated any selection for Arf LOH. Thus, our data reveal important insights into the p53 pathway in retinoblastoma and show that Arf is a key collaborator with Rb in retinoblastoma suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.